Adding belimumab improves renal outcome in lupus nephritis

Adding belimumab improves renal outcome in lupus nephritis

(HealthDay)—The addition of belimumab versus placebo to standard therapy increases the likelihood of a primary efficacy renal response in patients with active lupus nephritis, according to a study published in the Sept. 17 issue of the New England Journal of Medicine.

Richard Furie, M.D., from the Donald and Barbara Zucker School of Medicine at Hofstra-Northwell in Great Neck, New York, and colleagues conducted a 104-week trial at 107 sites in 21 countries involving adults with biopsy-proven, active lupus nephritis. A total of 448 participants were randomly assigned to receive either intravenous belimumab or matching in addition to standard therapy in a 1:1 ratio.

The researchers found that significantly more patients in the belimumab versus had a primary efficacy renal response (43 versus 32 percent; odds ratio, 1.6; 95 percent confidence interval, 1.0 to 2.3; P = 0.03) and a complete renal response (30 versus 20 percent; odds ratio, 1.7; 95 percent confidence interval, 1.1 to 2.7; P = 0.02) at week 104. Compared with those who received placebo, patients who received belimumab had a for a renal-related event or death (hazard ratio, 0.51; 95 percent confidence interval, 0.34 to 0.77; P = 0.001).

"This history-making clinical trial is the first successful study after decades of attempts with other lupus nephritis therapies," Furie said in a statement. "This trial will hopefully lead to the U.S. Food and Drug Administration's approval to extend belimumab's use to lupus nephritis, which represents the greatest unmet need for patients with systemic lupus erythematosus."

Several authors disclosed financial ties to , including GlaxoSmithKline, which manufactures belimumab and funded the study.


Explore further

Darolutamide boosts survival in nonmetastatic prostate cancer

More information: Abstract/Full Text (subscription or payment may be required)
Editorial (subscription or payment may be required)
Journal information: New England Journal of Medicine

Copyright © 2020 HealthDay. All rights reserved.

Citation: Adding belimumab improves renal outcome in lupus nephritis (2020, September 17) retrieved 22 October 2020 from https://medicalxpress.com/news/2020-09-adding-belimumab-renal-outcome-lupus.html
This document is subject to copyright. Apart from any fair dealing for the purpose of private study or research, no part may be reproduced without the written permission. The content is provided for information purposes only.
3 shares

Feedback to editors

User comments